Results from clinical study of BBS-Bioactive Bone Substitutes’ ARTEBONE® paste showed a fusion rate comparable with that of autograft. ARTEBONE paste was used as a bone void filler in the ankle and subtalar joints. Thirty-four subjects were enrolled at five sites in Finland and Poland, with results compared to the literature references on autograft, the gold standard for fusion.
Primary results demonstrated that the fusion rate with ARTEBONE paste is comparable with the fusion rate with autograft, without safety concerns or product related complications. It offers an alternative to the known risks and morbidity associated with autograft and synthetic bone growth factor products.
ARTEBONE comprises a ready-to-use mineral scaffold and bone proteins that promote bone growth in the extremities, scapula and pelvis.
BBS expects to receive approval under the CE Mark and commercial launch in Europe within 12 months.
Results from clinical study of BBS-Bioactive Bone Substitutes' ARTEBONE® paste showed a fusion rate comparable with that of autograft. ARTEBONE paste was used as a bone void filler in the ankle and subtalar joints. Thirty-four subjects were enrolled at five sites in Finland and Poland, with results compared to the literature references on...
Results from clinical study of BBS-Bioactive Bone Substitutes’ ARTEBONE® paste showed a fusion rate comparable with that of autograft. ARTEBONE paste was used as a bone void filler in the ankle and subtalar joints. Thirty-four subjects were enrolled at five sites in Finland and Poland, with results compared to the literature references on autograft, the gold standard for fusion.
Primary results demonstrated that the fusion rate with ARTEBONE paste is comparable with the fusion rate with autograft, without safety concerns or product related complications. It offers an alternative to the known risks and morbidity associated with autograft and synthetic bone growth factor products.
ARTEBONE comprises a ready-to-use mineral scaffold and bone proteins that promote bone growth in the extremities, scapula and pelvis.
BBS expects to receive approval under the CE Mark and commercial launch in Europe within 12 months.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
